Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Kronos Bio Announces First Patient Dosed In AGILITY Phase 3 Clinical Trial Of Entospletinib In Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of
HC Wainwright & Co. Maintains Buy on Kronos Bio, Raises Price Target to $36
HC Wainwright & Co. analyst Robert Burns maintains Kronos Bio (NASDAQ:KRON) with a Buy and raises the price target from $35 to $36.
Kronos Bio Q3 EPS $(0.61) Up From $(6.48) YoY
Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.61) per share. This is a 90.59 percent increase over losses of $(6.48) per share from the same period last year.
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen’s Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 12)